Last Updated : September 13, 2022
Details
FilesGeneric Name:
cenegermin
Project Status:
Complete
Therapeutic Area:
Neurotrophic keratitis
Manufacturer:
Dompé Farmaceutici S.p.A
Brand Name:
Oxervate
Project Line:
Reimbursement Review
Project Number:
SR0704-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults who have failed conventional non-surgical treatments.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient/clinician input open | 02-Sep-21 |
| Call for patient/clinician input closed | 25-Oct-21 |
| Clarification:
- Patient input submission received from the Canadian Organization for Rare Disorders |
|
| Submission received | 29-Oct-21 |
| Submission accepted | 15-Nov-21 |
| Review initiated | 16-Nov-21 |
| Draft CADTH review report(s) provided to sponsor for comment | 08-Feb-22 |
| Deadline for sponsors comments | 17-Feb-22 |
| CADTH review report(s) and responses to comments provided to sponsor | 14-Apr-22 |
| Expert committee meeting (initial) | 27-Apr-22 |
| Draft recommendation issued to sponsor | 09-May-22 |
| Draft recommendation posted for stakeholder feedback | 26-May-22 |
| End of feedback period | 09-Jun-22 |
| Final recommendation issued to sponsor and drug plans | 23-Jun-22 |
| Final recommendation posted | 12-Jul-22 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 08-Jul-22 |
| CADTH review report(s) posted | 13-Sep-22 |
Files
Last Updated : September 13, 2022